INSM / Insmed Incorporated - SEC-arkiveringar, Årsredovisning, Fullmaktsutlåtande

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTE

Exhibit 25.1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) [] COMPUTERSHARE TRUST COMPANY, NATIONAL ASSOCIATION (Exact name of trustee as specified in its charter)

CALCULATION OF FILING FEE TABLES Form S-3 (Form Type) INSMED INCORPORATED (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities

Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-3 (Form Type) INSMED INCORPORATED (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid In Connection with Unsold Securities to be carried Forward Newly Registered Securities Fees to Be Paid Equity Common Stock, $0.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2026 INSMED INCORPORATED

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2026 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission File N

As filed with the Securities and Exchange Commission on May 15, 2026

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on May 15, 2026 Registration No.

Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update — Total Company Revenues of $306.0 Million for the First Quarter of 2026— —BRINSUPRI® (brensocatib) Revenues of $207.9 Million for the First Quarter of 2026, Reflecting

Exhibit 99.1 Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update — Total Company Revenues of $306.0 Million for the First Quarter of 2026— —BRINSUPRI® (brensocatib) Revenues of $207.9 Million for the First Quarter of 2026, Reflecting 44% Growth Over the Fourth Quarter of 2025— — ARIKAYCE® (amikacin liposome inhalation suspension) Revenues of $98.1 Million for the First

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-30739 INSMED INC

May 7, 2026 First-Quarter 2026 Earnings Presentation Forward Looking Statements The forward-looking statements in this presentation are based upon the Company’s current expectations and beliefs, and involve known and unknown risks, uncertainties and

Exhibit 99.2 May 7, 2026 First-Quarter 2026 Earnings Presentation Forward Looking Statements The forward-looking statements in this presentation are based upon the Company’s current expectations and beliefs, and involve known and unknown risks, uncertainties and other factors, which may cause the Company’s actual results, performance and achievements and the timing of certain events to differ mate

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2026 INSMED INCORPORATED (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2026 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission File Nu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 7, 2026 INSMED INCORPORATED

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 7, 2026 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission File

Insmed Provides Clinical Update on Phase 2b CEDAR Study —Study Did Not Meet Primary or Secondary Efficacy Endpoints; Insmed Will Discontinue HS Program— —Safety Was Consistent with Previous Studies and No New Safety Signals Were Identified for Either

Exhibit 99.1 Insmed Provides Clinical Update on Phase 2b CEDAR Study —Study Did Not Meet Primary or Secondary Efficacy Endpoints; Insmed Will Discontinue HS Program— —Safety Was Consistent with Previous Studies and No New Safety Signals Were Identified for Either Dose of Brensocatib— BRIDGEWATER, N.J., Apr. 7, 2026 - Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical compa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Schedule 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO.   )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Schedule 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO.   ) Filed by the Registrant x Filed by a Party other than the Registrant  o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x De

ARS

2025 Annual Report Jane, Living with Bronchiectasis Jane, living with non-cystic fibrosis bronchiectasis (NCFB)Further has no finish line.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Schedule 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO.   )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Schedule 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO.   ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Def

March 23, 2026 Topline Results of Phase 3b ENCORE Study of ARIKAYCE® in Patients with Newly Diagnosed MAC Lung Infection Not Yet Treated With Antibiotics MAC: Mycobacterium avium complex lung disease | ARIKAYCE is approved in the U.S. as ARIKAYCE (am

Exhibit 99.2 March 23, 2026 Topline Results of Phase 3b ENCORE Study of ARIKAYCE® in Patients with Newly Diagnosed MAC Lung Infection Not Yet Treated With Antibiotics MAC: Mycobacterium avium complex lung disease | ARIKAYCE is approved in the U.S. as ARIKAYCE (amikacin liposome inhalation suspension), in Europe as ARIKAYCE Liposomal 590 mg Nebuliser Dispersion, and in Japan as ARIKAYCE inhalation

Insmed Announces Positive Topline Results from Phase 3b ENCORE Study of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with MAC Lung Disease —The Study Met Primary and All Multiplicity-Controlled Secondary Culture Conversion Endpoint

Exhibit 99.1 Insmed Announces Positive Topline Results from Phase 3b ENCORE Study of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with MAC Lung Disease —The Study Met Primary and All Multiplicity-Controlled Secondary Culture Conversion Endpoints, Demonstrating Statistically Significant and Clinically Meaningful Improvements in Respiratory Symptom Score and Culture Conversion Rat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2026 INSMED INCORPORATE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2026 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction (Commission (IRS Employer of incor

INSMED INCORPORATED NON-QUALIFIED STOCK OPTION AGREEMENT UNDER THE 2025 INDUCEMENT PLAN FOR NON-U.S. PARTICIPANTS

Exhibit 10.4.6 INSMED INCORPORATED NON-QUALIFIED STOCK OPTION AGREEMENT UNDER THE 2025 INDUCEMENT PLAN FOR NON-U.S. PARTICIPANTS No. of shares subject to Option: /$AwardsGranted$/ THIS NON-QUALIFIED STOCK OPTION AGREEMENT (this “Agreement”) dated this /$GrantDate$/, between INSMED INCORPORATED, a Virginia corporation (the “Company”), and /$ParticipantName$/ (“Participant”), is made pursuant and su

INSMED INCORPORATED PERFORMANCE-BASED RESTRICTED STOCK UNIT AWARD AGREEMENT UNDER THE AMENDED AND RESTATED 2019 INCENTIVE PLAN FOR NON-U.S. GRANTEES

Exhibit 10.3.11 INSMED INCORPORATED PERFORMANCE-BASED RESTRICTED STOCK UNIT AWARD AGREEMENT UNDER THE AMENDED AND RESTATED 2019 INCENTIVE PLAN FOR NON-U.S. GRANTEES Grantee Name: /$ParticipantName$/ Target Number of PSUs: /$AwardsGranted$/ Grant Date: /$GrantDate$/ Pursuant to the Insmed Incorporated Amended and Restated 2019 Incentive Plan (the “Plan”) as amended through the date hereof and this

INSMED INCORPORATED NON-QUALIFIED STOCK OPTION AGREEMENT UNDER THE AMENDED AND RESTATED 2019 INCENTIVE PLAN FOR U.S. PARTICIPANTS

Exhibit 10.3.8 INSMED INCORPORATED NON-QUALIFIED STOCK OPTION AGREEMENT UNDER THE AMENDED AND RESTATED 2019 INCENTIVE PLAN FOR U.S. PARTICIPANTS No. of shares subject to Option: /$AwardsGranted$/ THIS NON-QUALIFIED STOCK OPTION AGREEMENT (this “Agreement”) dated this /$GrantDate$/, between INSMED INCORPORATED, a Virginia corporation (the "Company"), and /$ParticipantName$/ ("Participant"), is made

AMENDMENT 1 to Product Agreement for Brensocatib Film Coated Tablets (10mg and 25mg) and Bottling between Patheon Inc. and Insmed Incorporated

Pursuant to Item 601(b)(10)(iv) of Regulation S-K, confidential information (indicated by [***]) has been omitted from Exhibit 10.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PUR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-30739 INSMED INCORPORAT

INSMED INCORPORATED NON-QUALIFIED STOCK OPTION AGREEMENT UNDER THE AMENDED AND RESTATED 2019 INCENTIVE PLAN FOR NON-U.S. PARTICIPANTS

Exhibit 10.3.9 INSMED INCORPORATED NON-QUALIFIED STOCK OPTION AGREEMENT UNDER THE AMENDED AND RESTATED 2019 INCENTIVE PLAN FOR NON-U.S. PARTICIPANTS No. of shares subject to Option: /$AwardsGranted$/ THIS NON-QUALIFIED STOCK OPTION AGREEMENT (this “Agreement”) dated this /$GrantDate$/, between INSMED INCORPORATED, a Virginia corporation (the "Company"), and /$ParticipantName$/ ("Participant"), is

INSMED INCORPORATED NON-QUALIFIED STOCK OPTION AGREEMENT UNDER THE 2025 INDUCEMENT PLAN FOR U.S. PARTICIPANTS

Exhibit 10.4.5 INSMED INCORPORATED NON-QUALIFIED STOCK OPTION AGREEMENT UNDER THE 2025 INDUCEMENT PLAN FOR U.S. PARTICIPANTS No. of shares subject to Option: /$AwardsGranted$/ THIS NON-QUALIFIED STOCK OPTION AGREEMENT (this “Agreement”) dated this /$GrantDate$/, between INSMED INCORPORATED, a Virginia corporation (the “Company”), and /$ParticipantName$/ (“Participant”), is made pursuant and subjec

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2026 INSMED INCORPOR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2026 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission F

Insmed Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Business Update —Company Expects Full-Year 2026 BRINSUPRI® (brensocatib) Revenues to Be at Least $1 Billion; Reiterates Full-Year 2026 ARIKAYCE® (amikacin liposome inhala

Exhibit 99.1 Insmed Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Business Update —Company Expects Full-Year 2026 BRINSUPRI® (brensocatib) Revenues to Be at Least $1 Billion; Reiterates Full-Year 2026 ARIKAYCE® (amikacin liposome inhalation suspension) Revenue Guidance of $450 Million to $470 Million— —Total Company Revenues of $606.4 Million for Full-Year 2025— —BRINSUP

February 19, 2026 Fourth-Quarter 2025 Earnings Presentation Forward Looking Statements The forward-looking statements in this presentation are based upon the Company’s current expectations and beliefs, and involve known and unknown risks, uncertainti

Exhibit 99.2 February 19, 2026 Fourth-Quarter 2025 Earnings Presentation Forward Looking Statements The forward-looking statements in this presentation are based upon the Company’s current expectations and beliefs, and involve known and unknown risks, uncertainties and other factors, which may cause the Company’s actual results, performance and achievements and the timing of certain events to diff

INSMED INCORPORATED PERFORMANCE-BASED RESTRICTED STOCK UNIT AWARD AGREEMENT UNDER THE AMENDED AND RESTATED 2019 INCENTIVE PLAN FOR U.S. GRANTEES

Exhibit 10.3.10 INSMED INCORPORATED PERFORMANCE-BASED RESTRICTED STOCK UNIT AWARD AGREEMENT UNDER THE AMENDED AND RESTATED 2019 INCENTIVE PLAN FOR U.S. GRANTEES Grantee Name: /$ParticipantName$/ Target Number of PSUs: /$AwardsGranted$/ Grant Date: /$GrantDate$/ Pursuant to the Insmed Incorporated Amended and Restated 2019 Incentive Plan (the “Plan”) as amended through the date hereof and this Perf

List of Subsidiaries January 2026 Name Jurisdiction of Incorporation Celtrix Pharmaceuticals, Inc. Delaware Insmed Gene Therapy LLC Delaware Insmed Limited England and Wales Insmed Holdings Limited Ireland Insmed Innovation UK Limited England and Wal

EXHIBIT 21.1 List of Subsidiaries January 2026 Name Jurisdiction of Incorporation Celtrix Pharmaceuticals, Inc. Delaware Insmed Gene Therapy LLC Delaware Insmed Limited England and Wales Insmed Holdings Limited Ireland Insmed Innovation UK Limited England and Wales Insmed Ireland Limited Ireland Insmed Netherlands Holdings B.V. The Netherlands Insmed Netherlands B.V. The Netherlands Insmed Germany

January 12, 2026 J.P. Morgan Healthcare Conference Presentation Forward Looking Statements The forward-looking statements in this presentation are based upon the Company’s current expectations and beliefs, and involve known and unknown risks, uncerta

Exhibit 99.2 January 12, 2026 J.P. Morgan Healthcare Conference Presentation Forward Looking Statements The forward-looking statements in this presentation are based upon the Company’s current expectations and beliefs, and involve known and unknown risks, uncertainties and other factors, which may cause the Company’s actual results, performance and achievements and the timing of certain events to

Insmed Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference — BRINSUPRI® (brensocatib) Unaudited Total Revenues of Approximately $144.6 Million for First Full Quarter of Launch; Approximately $172.7 Million for Full-Year 2025— —A

Exhibit 99.1 Insmed Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference — BRINSUPRI® (brensocatib) Unaudited Total Revenues of Approximately $144.6 Million for First Full Quarter of Launch; Approximately $172.7 Million for Full-Year 2025— —ARIKAYCE® (amikacin liposome inhalation suspension) Exceeds the Upper End of Guidance Range for Full-Year 2025 with Unaudited Global Reven

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2026 INSMED INCORPORAT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2026 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission Fil

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 17, 2025 INSMED INCORPOR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 17, 2025 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission F

Insmed Provides Clinical and Business Update —Phase 2b BiRCh Study of Brensocatib in CRSsNP Did Not Meet Primary or Secondary Efficacy Endpoints; Safety Consistent with Previous Studies; Insmed Discontinues CRSsNP Program— —Company Acquires Phase 2 R

Exhibit 99.1 Insmed Provides Clinical and Business Update —Phase 2b BiRCh Study of Brensocatib in CRSsNP Did Not Meet Primary or Secondary Efficacy Endpoints; Safety Consistent with Previous Studies; Insmed Discontinues CRSsNP Program— —Company Acquires Phase 2 Ready Monoclonal Antibody for Potential Respiratory and Immunological & Inflammatory Indications— BRIDGEWATER, N.J., December 17, 2025 - I

European Commission Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment Approved for Non-Cystic Fibrosis Bronchiectasis in the European Union — Non-Cystic Fibrosis Bronchiectasis (NCFB) Is a Serious, Progressive Lung Disease That Can Le

Exhibit 99.1 European Commission Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment Approved for Non-Cystic Fibrosis Bronchiectasis in the European Union — Non-Cystic Fibrosis Bronchiectasis (NCFB) Is a Serious, Progressive Lung Disease That Can Lead to Permanent Lung Damage — — BRINSUPRI Is a First-in-Disease, First-in-Class DPP1 Inhibitor Targeting Neutrophilic Inflammation — — BR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2025 INSMED INCORPOR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2025 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission F

FIRST AMENDMENT

Exhibit 10.1 Pursuant to Item 601(b)(10)(iv) of Regulation S-K, confidential information (indicated by [***]) has been omitted from Exhibit 10.26 because it (i) is not material and (ii) is the type of information the Company both customarily and actually treats as private or confidential. FIRST AMENDMENT This First Amendment to Amended and Restated Loan Agreement and Guaranty and Security Agreemen

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2025 INSMED INCORPORA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2025 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission Fi

Insmed Reports Third-Quarter 2025 Financial Results and Provides Business Update —BRINSUPRI™ (brensocatib) Approved by FDA as First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis; Positive CHMP Opinion Adopted in the European Union and App

Exhibit 99.1 Insmed Reports Third-Quarter 2025 Financial Results and Provides Business Update —BRINSUPRI™ (brensocatib) Approved by FDA as First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis; Positive CHMP Opinion Adopted in the European Union and Application Accepted in Japan— —BRINSUPRI Total Revenue of $28.1 Million for the Third Quarter of 2025— —ARIKAYCE® (amikacin liposome inhala

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-30739 INSMED

October 30, 2025 Third-Quarter 2025 Earnings Presentation Forward Looking Statements TPIP: Treprostinil Palmitil Inhalation Powder | MAC / MAC LD: Mycobacterium avium complex lung disease | FDA: Food & Drug Administration The forward-looking statemen

Exhibit 99.2 October 30, 2025 Third-Quarter 2025 Earnings Presentation Forward Looking Statements TPIP: Treprostinil Palmitil Inhalation Powder | MAC / MAC LD: Mycobacterium avium complex lung disease | FDA: Food & Drug Administration The forward-looking statements in this presentation are based upon the Company’s current expectations and beliefs, and involve known and unknown risks, uncertainties

144

144 0001182633 XXXXXXXX LIVE 0001104506 INSMED Inc 000-30739 700 US HIGHWAY 202/206 BRIDGEWATER NJ 08807 908-977-9900 SHAROKY MELVIN MD Director Common Merrill Lynch 4705 S Apopka Vineland Rd Suite 203 Orlando FL 32819 10000 1450000.

144

144 0001401017 XXXXXXXX LIVE 0001104506 INSMED Inc 000-30739 700 US HIGHWAY 202/206 BRIDGEWATER NJ 08807 908-977-9900 Schaeffer Orlov S Nicole Officer Common Merrill Lynch 1800 K ST NW Suite 800 Washington DC 20006 76520 11127662.

144

144 0001796960 XXXXXXXX LIVE 0001104506 INSMED Inc 000-30739 700 US HIGHWAY 202/206 BRIDGEWATER NJ 08807 908-977-9900 Flammer Martina M.

144

144 0001870278 XXXXXXXX LIVE 0001104506 INSMED Inc 000-30739 700 US HIGHWAY 202/206 BRIDGEWATER NJ 08807 908-977-9900 Smith Michael Alexander Officer Common Merrill Lynch 1800 K ST NW Suite 800 Washington DC 20006 24272 3491647.

FDA Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease — Approximately 500,000 U.S. Patients Are Diagnosed with Non-Cystic Fibrosis Bronchiectasis (NCFB), a Progre

Exhibit 99.1 FDA Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease — Approximately 500,000 U.S. Patients Are Diagnosed with Non-Cystic Fibrosis Bronchiectasis (NCFB), a Progressive Disease That Can Lead to Permanent Lung Damage — — BRINSUPRI 10 mg and 25 mg Doses Approved for the Treatment of NCFB — — BRINSUPRI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2025 INSMED INCORPORAT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2025 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission Fil

August 12, 2025 FDA Approval of BRINSUPRI™ for Patients with Non-Cystic Fibrosis Bronchiectasis FDA: Food & Drug Administration

Exhibit 99.2 August 12, 2025 FDA Approval of BRINSUPRI™ for Patients with Non-Cystic Fibrosis Bronchiectasis FDA: Food & Drug Administration Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. "Forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995, are statements th

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-30739 INSMED INCO

Insmed Reports Second-Quarter 2025 Financial Results and Provides Business Update —ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $107.4 Million for the Second Quarter of 2025, Reflecting 19% Growth Over the Second Quarter of 20

Exhibit 99.1 Insmed Reports Second-Quarter 2025 Financial Results and Provides Business Update —ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $107.4 Million for the Second Quarter of 2025, Reflecting 19% Growth Over the Second Quarter of 2024— —NDA for Brensocatib in Patients with Bronchiectasis Remains on Track, with a PDUFA Target Action Date of August 12, 2025— —TPIP Prog

August 7, 2025 Second-Quarter 2025 Earnings Presentation Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. “Forward-looking statements,” as that term is defined in the P

Exhibit 99.2 August 7, 2025 Second-Quarter 2025 Earnings Presentation Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. “Forward-looking statements,” as that term is defined in the Private Securities Litigation Reform Act of 1995, are statements that are not historical facts and involve a number of risks and uncertain

www.insmed.com 700 US Highway 202/206 | Bridgewater, NJ 08807 | Phone: 908-977-9900 | Fax: 908-526-4026

Exhibit 10.1 April 16, 2025 Drayton Wise [***] Dear Drayton: This letter, upon signature by the parties, will constitute our agreement (“Agreement”) effective April 17, 2025 (the “Effective Date”) concerning the services of J. Drayton Wise (“Consultant”) as a consultant to Insmed Incorporated (“Company”). 1.Services. Consultant will provide consulting services to Company, as may be requested by th

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 INSMED INCORPORATE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission File

Insmed Announces Pricing of $750 Million Public Offering of Common Stock

Exhibit 99.2 Insmed Announces Pricing of $750 Million Public Offering of Common Stock BRIDGEWATER, N.J., June 11, 2025 /PRNewswire/ - Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it priced an underwritten public offering of 7

INSMED INCORPORATED Common Stock, Par Value $0.01 Per Share Underwriting Agreement

Exhibit 1.1 EXECUTION VERSION INSMED INCORPORATED Common Stock, Par Value $0.01 Per Share Underwriting Agreement June 11, 2025 Goldman Sachs & Co. LLC Leerink Partners LLC As representatives (the “Representatives”) of the several Underwriters named in Schedule I hereto, c/o Goldman Sachs & Co. LLC 200 West Street, New York, New York 10282 c/o Leerink Partners LLC 53 State Street, 40th Floor Boston

Insmed Announces Proposed $650 Million Public Offering of Common Stock

Exhibit 99.1 Insmed Announces Proposed $650 Million Public Offering of Common Stock BRIDGEWATER, N.J., June 11, 2025 /PRNewswire/ - Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it intends to offer and sell $650 million of sha

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2025 INSMED INCORPORATED

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2025 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction (Commission (IRS Employer of incorp

7,812,500 Shares

TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration Number 333-272088 PROSPECTUS SUPPLEMENT (To Prospectus dated May 19, 2023) 7,812,500 Shares   Common Stock We are offering 7,812,500 shares of our common stock.

CALCULATION OF FILING FEE TABLE (Form Type) Insmed Incorporated (Exact Name of Registrant as Specified in its Charter) Table 1 - Newly Registered Securities

Exhibit 107 CALCULATION OF FILING FEE TABLE 424(b)(5) (Form Type) Insmed Incorporated (Exact Name of Registrant as Specified in its Charter) Table 1 - Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(2) Fees to be Paid Equity Common Stock, par value $0.

SUBJECT TO COMPLETION, DATED JUNE 11, 2025

TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and may be changed.

Insmed Announces Positive Topline Results from Phase 2b Study of Treprostinil Palmitil Inhalation Powder (TPIP) as Once-Daily Therapy in Patients with Pulmonary Arterial Hypertension

Exhibit 99.1 Insmed Announces Positive Topline Results from Phase 2b Study of Treprostinil Palmitil Inhalation Powder (TPIP) as Once-Daily Therapy in Patients with Pulmonary Arterial Hypertension –The Study Met Primary and All Secondary Efficacy Endpoints– ▫ Statistically Significant 35% Placebo-Adjusted Reduction from Baseline in Pulmonary Vascular Resistance for the Primary Endpoint (p<0.001) ▫

June 10, 2025 Topline Results of Phase 2b Study of TPIP in PAH Patients TPIP: Treprostinil Palmitil Inhalation Powder | PAH: pulmonary arterial hypertension Forward Looking Statements This presentation contains forward-looking statements that involve

Exhibit 99.2 June 10, 2025 Topline Results of Phase 2b Study of TPIP in PAH Patients TPIP: Treprostinil Palmitil Inhalation Powder | PAH: pulmonary arterial hypertension Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. “Forward-looking statements,” as that term is defined in the Private Securities Litigation Reform A

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2025 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2025 INSMED INCORPORATED

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2025 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission File N

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2025 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission File N

CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) Insmed Incorporated (Exact Name of Registrant as Specified in its Charter) Table 1 - Newly Registered Securities

Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) Insmed Incorporated (Exact Name of Registrant as Specified in its Charter) Table 1 - Newly Registered Securities (1) Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee (2)(3) Equity Common Stock, par value $0.

As filed with the Securities and Exchange Commission on May 16, 2025

As filed with the Securities and Exchange Commission on May 16, 2025 Registration No.

INSMED INCORPORATED RESTRICTED STOCK UNIT AWARD AGREEMENT UNDER THE 2025 INDUCEMENT PLAN FOR NON-U.S. GRANTEES

INSMED INCORPORATED RESTRICTED STOCK UNIT AWARD AGREEMENT UNDER THE 2025 INDUCEMENT PLAN FOR NON-U.

May 8, 2025 First-Quarter 2025 Earnings Presentation Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. “Forward-looking statements,” as that term is defined in the Priva

Exhibit 99.2 May 8, 2025 First-Quarter 2025 Earnings Presentation Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. “Forward-looking statements,” as that term is defined in the Private Securities Litigation Reform Act of 1995, are statements that are not historical facts and involve a number of risks and uncertainties

INSMED INCORPORATED NON-QUALIFIED STOCK OPTION AGREEMENT UNDER THE 2025 INDUCEMENT PLAN FOR NON-U.S. PARTICIPANTS

INSMED INCORPORATED NON-QUALIFIED STOCK OPTION AGREEMENT UNDER THE 2025 INDUCEMENT PLAN FOR NON-U.

Insmed Reports First-Quarter 2025 Financial Results and Provides Business Update —ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $92.8 Million for the First Quarter of 2025, Reflecting 23% Growth Over the First Quarter of 2024—

Exhibit 99.1 Insmed Reports First-Quarter 2025 Financial Results and Provides Business Update —ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $92.8 Million for the First Quarter of 2025, Reflecting 23% Growth Over the First Quarter of 2024— —NDA for Brensocatib in Patients with Bronchiectasis Remains on Track, with a PDUFA Target Action Date of August 12, 2025— —Phase 2b Stud

INSMED INCORPORATED RESTRICTED STOCK UNIT AWARD AGREEMENT UNDER THE 2025 INDUCEMENT PLAN FOR U.S. GRANTEES

INSMED INCORPORATED RESTRICTED STOCK UNIT AWARD AGREEMENT UNDER THE 2025 INDUCEMENT PLAN FOR U.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-30739 INSMED INC

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission File Nu

INSMED INCORPORATED NON-QUALIFIED STOCK OPTION AGREEMENT UNDER THE 2025 INDUCEMENT PLAN FOR U.S. PARTICIPANTS

INSMED INCORPORATED NON-QUALIFIED STOCK OPTION AGREEMENT UNDER THE 2025 INDUCEMENT PLAN FOR U.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2025 INSMED INCORPORATE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2025 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2025 INSMED INCORPORA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2025 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission Fi

Insmed Announces Redemption of all $569.5 Million of Remaining Outstanding 0.75% Convertible Senior Notes Due 2028

Exhibit 99.1 Insmed Announces Redemption of all $569.5 Million of Remaining Outstanding 0.75% Convertible Senior Notes Due 2028 BRIDGEWATER, N.J., April 24, 2025/PRNewswire/ - Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it h

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 16, 2025 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Schedule 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO.   )

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Schedule 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO.   ) Filed by the Registrant x Filed by a Party other than the Registrant  o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Schedule 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO.   )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Schedule 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO.   ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Def

ARS

Annual Report Ready. 2024Readiness is not a milestone. It’s not a moment. Readiness is a state of mind. It’s built on cultural cohesion, adaptive thinking, and the willingness to fail. Readiness is fueled by intention. At Insmed, we will always be ready to transform the lives of patients and families and change what it means to live with a serious disease. The success we anticipate in 2025 and bey

Insmed Announces that FDA Does Not Currently Plan to Hold Advisory Committee Meeting to Discuss New Drug Application for Brensocatib in Patients with Bronchiectasis —FDA Reaffirms Application is Under Priority Review with a PDUFA Target Action Date o

Exhibit 99.1 Insmed Announces that FDA Does Not Currently Plan to Hold Advisory Committee Meeting to Discuss New Drug Application for Brensocatib in Patients with Bronchiectasis —FDA Reaffirms Application is Under Priority Review with a PDUFA Target Action Date of August 12, 2025— BRIDGEWATER, N.J., February 24, 2025 /PRNewswire/ - Insmed Incorporated (Nasdaq: INSM), a people-first global biopharm

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2025 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission F

INSMED INCORPORATED 2025 INDUCEMENT PLAN

Exhibit 4.1 INSMED INCORPORATED 2025 INDUCEMENT PLAN 1. Purpose The purpose of the Plan is to provide equity compensation to certain eligible individuals in order to induce such individuals to enter into employment with the Company or its Subsidiaries. The Plan is intended to meet the requirements of a plan providing for inducement grants under Rule 5635(c)(4) of the Nasdaq Listing Rules and shall

CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) Insmed Incorporated (Exact Name of Registrant as Specified in its Charter)

Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) Insmed Incorporated (Exact Name of Registrant as Specified in its Charter) (1) Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee (2) Equity Common Stock, par value $0.

List of Subsidiaries January 2025 Name Jurisdiction of Incorporation Celtrix Pharmaceuticals, Inc. Delaware Insmed Gene Therapy LLC Delaware Insmed Limited England and Wales Insmed Holdings Limited Ireland Insmed Innovation UK Limited England and Wal

EXHIBIT 21.1 List of Subsidiaries January 2025 Name Jurisdiction of Incorporation Celtrix Pharmaceuticals, Inc. Delaware Insmed Gene Therapy LLC Delaware Insmed Limited England and Wales Insmed Holdings Limited Ireland Insmed Innovation UK Limited England and Wales Insmed Ireland Limited Ireland Insmed Netherlands Holdings B.V. The Netherlands Insmed Netherlands B.V. The Netherlands Insmed Germany

FIRST AMENDMENT TO REVENUE INTEREST PURCHASE AGREEMENT

Exhibit 10.25.1 Pursuant to Item 601(b)(10)(iv) of Regulation S-K, confidential information (indicated by [***]) has been omitted from Exhibit 10.25.1 because it (i) is not material and (ii) is the type of information the Company both customarily and actually treats as private or confidential. FIRST AMENDMENT TO REVENUE INTEREST PURCHASE AGREEMENT This FIRST AMENDMENT TO REVENUE INTEREST PURCHASE

As filed with the Securities and Exchange Commission on February 20, 2025

As filed with the Securities and Exchange Commission on February 20, 2025 Registration No.

February 2025 Investor Presentation Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. “Forward-looking statements,” as that term is defined in the Private Securities Lit

Exhibit 99.2 February 2025 Investor Presentation Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. “Forward-looking statements,” as that term is defined in the Private Securities Litigation Reform Act of 1995, are statements that are not historical facts and involve a number of risks and uncertainties. Words herein su

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 18, 2025 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission F

Master Commercial Manufacturing Services Agreement PATHEON INC. a company existing under the laws of Canada, with a place of business at, Whitby Operations: 111 Consumers Drive, Whitby, Ontario L1N 5Z5, Canada ("Patheon"), - and - INSMED INCORPORATED

Exhibit 10.24 Pursuant to Item 601(b)(10)(iv) of Regulation S-K, confidential information (indicated by [***]) has been omitted from Exhibit 10.24 because it (i) is not material and (ii) is the type of information the Company both customarily and actually treats as private or confidential. Master Commercial Manufacturing Services Agreement PARTIES PATHEON INC. a company existing under the laws of

AMENDMENT NO. 2 TO COMMERCIALIZATION AGREEMENT BETWEEN INSMED INCORPORATED AND PARI PHARMA GMBH

Exhibit 10.19.2 Pursuant to Item 601(b)(10)(iv) of Regulation S-K, confidential information (indicated by [***]) has been omitted from Exhibit 10.19.2 because it (i) is not material and (ii) is the type of information the Company both customarily and actually treats as private or confidential. AMENDMENT NO. 2 TO COMMERCIALIZATION AGREEMENT BETWEEN INSMED INCORPORATED AND PARI PHARMA GMBH This seco

Insmed Incorporated Insider Trading Policy Effective June 10, 2024

Exhibit 19.1 Insmed Incorporated Insider Trading Policy Effective June 10, 2024 I.Introduction and Purpose This Insider Trading Policy (this “Policy”) prohibits any trading of securities while in possession of material nonpublic information gained in the course of performing services for Insmed Incorporated (the “Company”) and any unauthorized disclosure of such information. The Company is subject

COMMERCIAL MANUFACTURING AND SUPPLY AGREEMENT

Exhibit 10.27 Pursuant to Item 601(b)(10)(iv) of Regulation S-K, confidential information (indicated by [***]) has been omitted from Exhibit 10.27 because it (i) is not material and (ii) is the type of information the Company both customarily and actually treats as private or confidential. COMMERCIAL MANUFACTURING AND SUPPLY AGREEMENT THIS COMMERCIAL MANUFACTURING AND SUPPLY AGREEMENT (the “Agreem

Insmed Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides Business Update —ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $104.4 Million for Fourth-Quarter and $363.7 Million for Full-Year 2024, Reflecting

Exhibit 99.1 Insmed Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides Business Update —ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $104.4 Million for Fourth-Quarter and $363.7 Million for Full-Year 2024, Reflecting 19% Annual Growth and Exceeding the Upper End of Full-Year 2024 Guidance Range— —Company Reiterates 2025 Global ARIKAYCE Revenue Guidance

PRODUCT AGREEMENT Product Agreement for Brensocatib Film Coated Tablets (10mg and 25mg) and Bottling

Exhibit 10.24.1 Pursuant to Item 601(b)(10)(iv) of Regulation S-K, confidential information (indicated by [***]) has been omitted from Exhibit 10.24.1 because it (i) is not material and (ii) is the type of information the Company both customarily and actually treats as private or confidential. PRODUCT AGREEMENT Product Agreement for Brensocatib Film Coated Tablets (10mg and 25mg) and Bottling This

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PUR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-30739 INSMED INCORPORAT

AMENDED AND RESTATED LOAN AGREEMENT Dated as of October 31, 2024 INSMED INCORPORATED (as Borrower, and a Credit Party), THE GUARANTORS SIGNATORY HERETO OR OTHERWISE PARTY HERETO FROM TIME TO TIME (as additional Credit Parties), BIOPHARMA CREDIT PLC (

Exhibit 10.26 Pursuant to Item 601(b)(10)(iv) of Regulation S-K, confidential information (indicated by [***]) has been omitted from Exhibit 10.26 because it (i) is not material and (ii) is the type of information the Company both customarily and actually treats as private or confidential. AMENDED AND RESTATED LOAN AGREEMENT Dated as of October 31, 2024 among INSMED INCORPORATED (as Borrower, and

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2025 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission Fi

FDA Grants Priority Review to Insmed’s Brensocatib for Treatment of Bronchiectasis with PDUFA Target Action Date Set for August 12, 2025 —Brensocatib Would be the First and Only Available Treatment for Bronchiectasis and First DPP1 Inhibitor, if Appr

Exhibit 99.1 FDA Grants Priority Review to Insmed’s Brensocatib for Treatment of Bronchiectasis with PDUFA Target Action Date Set for August 12, 2025 —Brensocatib Would be the First and Only Available Treatment for Bronchiectasis and First DPP1 Inhibitor, if Approved— BRIDGEWATER, N.J., February 6, 2025 /PRNewswire/ - Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical comp

Insmed Provides Business Update at 43rd Annual J.P. Morgan Healthcare Conference —ARIKAYCE® (amikacin liposome inhalation suspension) Exceeds the Upper End of Guidance Range for Full-Year 2024 with Unaudited Global Revenues of Approximately $363.7 Mi

Exhibit 99.1 Insmed Provides Business Update at 43rd Annual J.P. Morgan Healthcare Conference —ARIKAYCE® (amikacin liposome inhalation suspension) Exceeds the Upper End of Guidance Range for Full-Year 2024 with Unaudited Global Revenues of Approximately $363.7 Million— —2025 Global ARIKAYCE Revenues Expected to be Between $405 Million and $425 Million, Reflecting Continued Double-Digit Growth Comp

January 13, 2025 JPMorgan Healthcare Conference Presentation Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. “Forward-looking statements,” as that term is defined in t

Exhibit 99.2 January 13, 2025 JPMorgan Healthcare Conference Presentation Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. “Forward-looking statements,” as that term is defined in the Private Securities Litigation Reform Act of 1995, are statements that are not historical facts and involve a number of risks and uncer

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2025 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission Fi

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2024 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission F

INSM / Insmed Incorporated / PRICE T ROWE ASSOCIATES INC /MD/ Passive Investment

SC 13G/A 1 insm13gasep24.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 13) INSMED INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 457669307 (CUSIP NUMBER) September 30, 2024 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant t

Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2024 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission Fi

Insmed Reports Third-Quarter 2024 Financial Results and Provides Business Update —ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $93.4 Million for the Third Quarter of 2024, Reflecting 18% Growth Over the Third Quarter of 2023—

Exhibit 99.1 Insmed Reports Third-Quarter 2024 Financial Results and Provides Business Update —ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $93.4 Million for the Third Quarter of 2024, Reflecting 18% Growth Over the Third Quarter of 2023— —NDA Submission for Brensocatib in Bronchiectasis Remains on Track for the Fourth Quarter of 2024 with Potential U.S. Launch Still Expect

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-30739 INSMED

INSM / Insmed Incorporated / Darwin Global Management, Ltd. Passive Investment

SC 13G 1 p24-2682sc13g.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Insmed Incorporated (Name of Issuer) Common stock, par value $0.01 per share (Title of Class of Securities) 457669307 (CUSIP Number) August 23, 2024 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designat

JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)

EX-99 2 p24-2682exhibit1.htm EXHIBIT 1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreem

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2024 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission File

INSMED INCORPORATED RESTRICTED STOCK UNIT AWARD AGREEMENT UNDER THE AMENDED AND RESTATED 2019 INCENTIVE PLAN FOR U.S. GRANTEES

Exhibit 10.1.3 INSMED INCORPORATED RESTRICTED STOCK UNIT AWARD AGREEMENT UNDER THE AMENDED AND RESTATED 2019 INCENTIVE PLAN FOR U.S. GRANTEES Grantee Name: /$ParticipantName$/ Number of RSUs: /$AwardsGranted$/ Grant Date: /$GrantDate$/ Pursuant to the Insmed Incorporated Amended and Restated 2019 Incentive Plan (the “Plan”) as amended through the date hereof and this Restricted Stock Unit Award Ag

Insmed Reports Second-Quarter 2024 Financial Results and Provides Business Update —ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $90.3 Million for the Second Quarter of 2024, Reflecting 17% Growth Over the Second Quarter of 202

Exhibit 99.1 Insmed Reports Second-Quarter 2024 Financial Results and Provides Business Update —ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $90.3 Million for the Second Quarter of 2024, Reflecting 17% Growth Over the Second Quarter of 2023— —U.S. Launch Readiness for Brensocatib in Bronchiectasis Remains on Track with NDA Submission Expected in the Fourth Quarter of 2024—

INSMED INCORPORATED NON-QUALIFIED STOCK OPTION AGREEMENT UNDER THE AMENDED AND RESTATED 2019 INCENTIVE PLAN FOR NON-U.S. PARTICIPANTS

Exhibit 10.1.2 INSMED INCORPORATED NON-QUALIFIED STOCK OPTION AGREEMENT UNDER THE AMENDED AND RESTATED 2019 INCENTIVE PLAN FOR NON-U.S. PARTICIPANTS No. of shares subject to Option: /$AwardsGranted$/ THIS NON-QUALIFIED STOCK OPTION AGREEMENT (this “Agreement”) dated this /$GrantDate$/, between INSMED INCORPORATED, a Virginia corporation (the "Company"), and /$ParticipantName$/ ("Participant"), is

COMMERCIALIZATION AGREEMENT

Pursuant to Item 601(b)(10)(iv) of Regulation S-K, confidential information (indicated by [***]) has been omitted from Exhibit 10.

AMENDMENT NO. 1 TO COMMERCIALIZATION AGREEMENT BETWEEN INSMED INCORPORATED AND PARI PHARMA GMBH

Pursuant to Item 601(b)(10)(iv) of Regulation S-K, confidential information (indicated by [***]) has been omitted from Exhibit 10.

INSMED INCORPORATED NONQUALIFIED STOCK OPTION INDUCEMENT AWARD AGREEMENT

Exhibit 10.3 INSMED INCORPORATED NONQUALIFIED STOCK OPTION INDUCEMENT AWARD AGREEMENT No. of shares subject to Option: /$AwardsGranted$/ THIS AGREEMENT dated this /$GrantDate$/ (this “Agreement”), between INSMED INCORPORATED, a Virginia corporation (the “Company”), and /$ParticipantName$/ (the “Participant”), is an inducement material to Participant’s entry into employment with the Company or a su

OMNIBUS AMENDMENT TO INSMED INCORPORATED INCENTIVE AWARDS AND INDUCEMENT AWARDS May 8, 2024

Exhibit 10.2 OMNIBUS AMENDMENT TO INSMED INCORPORATED INCENTIVE AWARDS AND INDUCEMENT AWARDS May 8, 2024 WHEREAS, Insmed Incorporated (the “Company”) sponsors and maintains the Insmed Incorporated 2013 Incentive Plan, the Insmed Incorporated 2015 Incentive Plan, the Insmed Incorporated 2017 Incentive Plan and the Insmed Incorporated Amended and Restated 2019 Incentive Plan (each, a “Plan” and toge

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-30739 INSMED INCO

INSMED INCORPORATED NON-QUALIFIED STOCK OPTION AGREEMENT UNDER THE AMENDED AND RESTATED 2019 INCENTIVE PLAN FOR U.S. PARTICIPANTS

Exhibit 10.1.1 INSMED INCORPORATED NON-QUALIFIED STOCK OPTION AGREEMENT UNDER THE AMENDED AND RESTATED 2019 INCENTIVE PLAN FOR U.S. PARTICIPANTS No. of shares subject to Option: /$AwardsGranted$/ THIS NON-QUALIFIED STOCK OPTION AGREEMENT (this “Agreement”) dated this /$GrantDate$/, between INSMED INCORPORATED, a Virginia corporation (the "Company"), and /$ParticipantName$/ ("Participant"), is made

INSMED INCORPORATED RESTRICTED STOCK UNIT AWARD AGREEMENT UNDER THE AMENDED AND RESTATED 2019 INCENTIVE PLAN FOR NON-U.S. GRANTEES

Exhibit 10.1.4 INSMED INCORPORATED RESTRICTED STOCK UNIT AWARD AGREEMENT UNDER THE AMENDED AND RESTATED 2019 INCENTIVE PLAN FOR NON-U.S. GRANTEES Grantee Name: /$ParticipantName$/ Number of RSUs: /$AwardsGranted$/ Grant Date: /$GrantDate$/ Pursuant to the Insmed Incorporated Amended and Restated 2019 Incentive Plan (the “Plan”) as amended through the date hereof and this Restricted Stock Unit Awar

INSMED INCORPORATED NONQUALIFIED STOCK OPTION INDUCEMENT AWARD AGREEMENT FOR NON-US EMPLOYEES

Exhibit 10.4 INSMED INCORPORATED NONQUALIFIED STOCK OPTION INDUCEMENT AWARD AGREEMENT FOR NON-US EMPLOYEES No. of shares subject to Option: /$AwardsGranted$/ THIS AGREEMENT dated this /$GrantDate$/ (this “Agreement”), between INSMED INCORPORATED, a Virginia corporation (the “Company”), and [NAME] (the “Participant”), is an inducement material to Participant’s entry into employment with the Company

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission File

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Patients With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study James D. Chalmers

Exhibit 99.2 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Patients With Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study James D. Chalmers,1 Pierre-Régis Burgel,2 Charles L. Daley,3 Anthony De Soyza,4 Charles S. Haworth,5 David Mauger,6 Kevin Mange,7 Ariel Teper,7 Carlos Fer

—New Graph Depicting 52-Week FEV1 Data Illustrate Significantly Less Decline in Lung Function for Brensocatib 25 mg Versus Placebo— —Additional Exploratory Endpoints to be Presented, Including FVC and Patient-Reported BEST Score—

Exhibit 99.1 Additional Positive Data from Pivotal ASPEN Study of Brensocatib in Patients with Bronchiectasis to be Presented at the 7th World Bronchiectasis Conference —New Graph Depicting 52-Week FEV1 Data Illustrate Significantly Less Decline in Lung Function for Brensocatib 25 mg Versus Placebo— —Additional Exploratory Endpoints to be Presented, Including FVC and Patient-Reported BEST Score— B

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 3, 2024 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission File N

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2024 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission File

Insmed Announces Redemption of all $225 Million of Outstanding 1.75% Convertible Senior Notes Due 2025

Exhibit 99.1 Insmed Announces Redemption of all $225 Million of Outstanding 1.75% Convertible Senior Notes Due 2025 BRIDGEWATER, N.J., June 27, 2024/PRNewswire/ - Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it has called all $225 million aggregate principal amount of its

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2024 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2024 INSMED INCORPORATED

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2024 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission File N

Insmed Incorporated Commercial Presentation June 4, 2024

Exhibit 99.1 Insmed Incorporated Commercial Presentation June 4, 2024 Forward Looking Statement Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. “Forward-looking statements,” as that term is defined in the Private Securities Litigation Reform Act of 1995, are statements that are not historical facts and involve a num

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2024 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction (Commission (IRS Employer of incorpo

INSMED INCORPORATED Common Stock, Par Value $0.01 Per Share Underwriting Agreement

Exhibit 1.1 EXECUTION VERSION INSMED INCORPORATED Common Stock, Par Value $0.01 Per Share Underwriting Agreement May 29, 2024 Goldman Sachs & Co. LLC Leerink Partners LLC As representatives (the “Representatives”) of the several Underwriters named in Schedule I hereto, c/o Goldman Sachs & Co. LLC 200 West Street, New York, New York 10282 c/o Leerink Partners LLC 53 State Street, 40th Floor Boston,

CALCULATION OF FILING FEE TABLE (Form Type) Insmed Incorporated (Exact Name of Registrant as Specified in its Charter) Table 1 - Newly Registered Securities

Exhibit 107 CALCULATION OF FILING FEE TABLE 424(b)(5) (Form Type) Insmed Incorporated (Exact Name of Registrant as Specified in its Charter) Table 1 - Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(2) Fees to be Paid Equity Common Stock, par value $0.

Insmed Announces Pricing of $650 Million Public Offering of Common Stock

Exhibit 99.2 Insmed Announces Pricing of $650 Million Public Offering of Common Stock BRIDGEWATER, N.J., May 30, 2024 /PRNewswire/ - Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it priced an underwritten public offering of 12,621,359 shares of its common stock at a price t

12,621,359 Shares

TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration Number 333-272088 PROSPECTUS SUPPLEMENT (To Prospectus dated May 19, 2023) 12,621,359 Shares   Common Stock We are offering 12,621,359 shares of our common stock.

Insmed Announces Proposed $500 Million Public Offering of Common Stock

Exhibit 99.1 Insmed Announces Proposed $500 Million Public Offering of Common Stock BRIDGEWATER, N.J., May 28, 2024 /PRNewswire/ - Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it intends to offer and sell $500 million of shares of its common stock in an underwritten public

The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has become effective by rule of the Securities and Exchange Commission. This preliminary prospectus su

TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration Number 333-272088 The information in this preliminary prospectus supplement is not complete and may be changed.

ASPEN Topline Results May 28, 2024 Forward Looking Statement Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. "Forward-looking statements," as that term is defined in t

Exhibit 99.2 ASPEN Topline Results May 28, 2024 Forward Looking Statement Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. "Forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995, are statements that are not historical facts and involve a number of risks and uncer

Insmed Announces Positive Topline Results from Landmark ASPEN Study of Brensocatib in Patients with Bronchiectasis —Phase 3 Study Achieves Primary Endpoint for Both Dosage Strengths of Brensocatib with Statistically Significant and Clinically Meaning

Exhibit 99.1 Insmed Announces Positive Topline Results from Landmark ASPEN Study of Brensocatib in Patients with Bronchiectasis —Phase 3 Study Achieves Primary Endpoint for Both Dosage Strengths of Brensocatib with Statistically Significant and Clinically Meaningful Reduction in Frequency of Pulmonary Exacerbations Versus Placebo— —Treatment with Brensocatib Also Achieves Statistical Significance

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2024 INSMED INCORPORATED

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2024 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission File N

As filed with the Securities and Exchange Commission on May 14, 2024

As filed with the Securities and Exchange Commission on May 14, 2024 Registration No.

CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) Insmed Incorporated (Exact Name of Registrant as Specified in its Charter) Table 1 - Newly Registered Securities

Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) Insmed Incorporated (Exact Name of Registrant as Specified in its Charter) Table 1 - Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2024 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission File N

May 2024 TPIP Phase 2 PH-ILD Topline Results & Phase 2 PAH Blended Blinded Data Update Forward Looking Statement Forward-Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. “Forwa

Exhibit 99.2 May 2024 TPIP Phase 2 PH-ILD Topline Results & Phase 2 PAH Blended Blinded Data Update Forward Looking Statement Forward-Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. “Forward-looking statements,” as that term is defined in the Private Securities Litigation Reform Act of 1995, are statements that are not hist

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-30739 INSMED INC

Insmed Reports First-Quarter 2024 Financial Results and Provides Business Update — ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $75.5 Million for the First Quarter of 2024, Reflecting 16% Annual Growth Over the First Quarter o

Exhibit 99.1 Insmed Reports First-Quarter 2024 Financial Results and Provides Business Update — ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $75.5 Million for the First Quarter of 2024, Reflecting 16% Annual Growth Over the First Quarter of 2023— —Company Reports Positive Topline Safety and Tolerability Data from the Phase 2 PH-ILD Study of TPIP with 79.3% of Patients Reach

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission File Nu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Schedule 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO.   )

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Schedule 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO.   ) Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box:  ☐ Preliminary Proxy Statement  ☐ Confidential, for Use of the Commission Only (as permitted by Ru

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Schedule 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Schedule 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2024 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PUR

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-30739

List of Subsidiaries January 2024 Name Jurisdiction of Incorporation Adrestia Therapeutics Inc. Delaware Celtrix Pharmaceuticals, Inc. Delaware Insmed Gene Therapy LLC Delaware Insmed Limited England and Wales Insmed Holdings Limited Ireland Insmed I

EXHIBIT 21.1 List of Subsidiaries January 2024 Name Jurisdiction of Incorporation Adrestia Therapeutics Inc. Delaware Celtrix Pharmaceuticals, Inc. Delaware Insmed Gene Therapy LLC Delaware Insmed Limited England and Wales Insmed Holdings Limited Ireland Insmed Innovation UK Limited England and Wales Insmed Ireland Limited Ireland Insmed Netherlands Holdings B.V. The Netherlands Insmed Netherlands

AMENDED AND RESTATED RECOUPMENT POLICY

Exhibit 97 AMENDED AND RESTATED RECOUPMENT POLICY I.Purpose. Insmed Incorporated (the “Company”) is establishing this amended and restated recoupment policy (this “Policy”) to appropriately align the interests of the Executive Officers with those of the Company. This Policy has been approved by the Board and is effective as of [October 2], 2023 (the “Effective Date”). This Policy is intended to co

Entry into a Material Definitive Agreement, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2024 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission F

Calculation of Filing Fee Tables (Form Type) INSMED INCORPORATED (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities

Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) INSMED INCORPORATED (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(1) Fee Rate Amount of Registration Fee(2) Newly Registered Securities Fees to Be Paid Equity Common Stock, $0.

Insmed Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Business Update —Topline Data from the Phase 3 ASPEN Trial of Brensocatib in Adult Patients with Bronchiectasis Remain on Track to Read Out in the Latter Part of Second-Q

Exhibit 99.1 Insmed Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Business Update —Topline Data from the Phase 3 ASPEN Trial of Brensocatib in Adult Patients with Bronchiectasis Remain on Track to Read Out in the Latter Part of Second-Quarter 2024— —Enrollment in the Phase 2 Study of TPIP in Patients with PH-ILD Completed in November 2023; Topline Data Expected in Second

INSMED INCORPORATED Shares of Common Stock ($0.01 par value per share) SALES AGREEMENT

Exhibit 10.1 Execution Version INSMED INCORPORATED Shares of Common Stock ($0.01 par value per share) SALES AGREEMENT February 22, 2024 LEERINK PARTNERS LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 Ladies and Gentlemen: Insmed Incorporated, a Virginia corporation (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC (the “Agent”), as follows:

Common Stock

TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-272088 PROSPECTUS SUPPLEMENT (To Prospectus dated May 19, 2023) $500,000,000   Common Stock We have entered into a sales agreement (the “Sales Agreement”) with Leerink Partners LLC (“Leerink Partners”) dated February 22, 2024, relating to shares of our common stock, par value $0.01 per share, offered by this prospectus supplem

INSM / Insmed Incorporated / T. Rowe Price Investment Management, Inc. Passive Investment

SC 13G/A 1 insm13gadec23.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) INSMED INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 457669307 (CUSIP NUMBER) December 31, 2023 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to

INSM / Insmed Incorporated / T. Rowe Price Investment Management, Inc. Passive Investment

SC 13G 1 insm13gdec23.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) INSMED INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 457669307 (CUSIP NUMBER) December 31, 2023 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to whic

INSM / Insmed Incorporated / PRICE T ROWE ASSOCIATES INC /MD/ Passive Investment

SC 13G/A 1 insm13gadec23.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 12) INSMED INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 457669307 (CUSIP NUMBER) December 31, 2023 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to

INSM / Insmed Incorporated / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv01192-insmedinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 9)* Name of issuer: Insmed Inc Title of Class of Securities: Common Stock CUSIP Number: 457669307 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule purs

INSM / Insmed Incorporated / BlackRock Inc. Passive Investment

SC 13G/A 1 us4576693075012524.txt us4576693075012524.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 11) INSMED INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 457669307 - (CUSIP Number) December 31, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to des

INSM / Insmed Incorporated / STATE STREET CORP Passive Investment

SC 13G/A 1 InsmedInc.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 EXIT FILING INSMED INC (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 457669307 (CUSIP NUMBER) 12/31/2023 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT TO WHICH THIS S

Insmed Provides Business Update at 42nd Annual J.P. Morgan Healthcare Conference —ARIKAYCE® (amikacin liposome inhalation suspension) Delivers Full-Year 2023 Revenues Exceeding the Upper End of Guidance Range with Unaudited Global Net Product Sales o

Exhibit 99.1 Insmed Provides Business Update at 42nd Annual J.P. Morgan Healthcare Conference —ARIKAYCE® (amikacin liposome inhalation suspension) Delivers Full-Year 2023 Revenues Exceeding the Upper End of Guidance Range with Unaudited Global Net Product Sales of Approximately $305.2 Million— —2024 Global ARIKAYCE Revenues Expected to be Between $340 Million and $360 Million, Reflecting Double-Di

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2024 INSMED INCORPORAT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2024 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission Fil

J.P. Morgan Healthcare Conference January 2024 Forward Looking Statement Forward-Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. "Forward-looking statements," as that term is

Exhibit 99.2 J.P. Morgan Healthcare Conference January 2024 Forward Looking Statement Forward-Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. "Forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995, are statements that are not historical facts and involve a number of ris

INSM / Insmed Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 8)* Name of issuer: Insmed Inc Title of Class of Securities: Common Stock CUSIP Number: 457669307 Date of Event Which Requires Filing of this Statement: October 31, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-

Insmed Reports Third-Quarter 2023 Financial Results and Provides Business Update —ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $79.1 Million for the Third Quarter of 2023 Reflects Highest Quarter of Sales Since Launch and 17%

Exhibit 99.1 Insmed Reports Third-Quarter 2023 Financial Results and Provides Business Update —ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $79.1 Million for the Third Quarter of 2023 Reflects Highest Quarter of Sales Since Launch and 17% Growth Compared to the Third Quarter of 2022— —Company Reiterates Full-Year 2023 Guidance Range for Global ARIKAYCE Revenues of $295 Mill

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2023 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission Fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-30739 INSMED

ARISE Topline Results September 5, 2023 Forward Looking Statement Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. "Forward-looking statements," as that term is defined

Exhibit 99.2 ARISE Topline Results September 5, 2023 Forward Looking Statement Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. "Forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995, are statements that are not historical facts and involve a number of risks and

INSMED ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 3 ARISE STUDY OF ARIKAYCE® (AMIKACIN LIPOSOME INHALATION SUSPENSION) IN PATIENTS WITH NTM LUNG DISEASE CAUSED BY MAC

Exhibit 99.1 INSMED ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 3 ARISE STUDY OF ARIKAYCE® (AMIKACIN LIPOSOME INHALATION SUSPENSION) IN PATIENTS WITH NTM LUNG DISEASE CAUSED BY MAC —QOL-B Respiratory Domain Shown to Work Effectively as Patient-Reported Outcome Tool in Patients with MAC Lung Disease; to be Proposed to FDA as Primary Endpoint in ENCORE with No Modifications— —Patients Treated with

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 5, 2023 INSMED INCORPOR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 5, 2023 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission F

INSMED INCORPORATED RESTRICTED STOCK UNIT AWARD AGREEMENT UNDER THE AMENDED AND RESTATED 2019 INCENTIVE PLAN FOR MEMBERS OF THE BOARD OF DIRECTORS

INSMED INCORPORATED RESTRICTED STOCK UNIT AWARD AGREEMENT UNDER THE AMENDED AND RESTATED 2019 INCENTIVE PLAN FOR MEMBERS OF THE BOARD OF DIRECTORS Grantee Name: [NAME] Number of RSUs: [AMOUNT] Grant Date: [DATE] Pursuant to the Insmed Incorporated Amended and Restated 2019 Incentive Plan (the “Plan”) as amended through the date hereof and this Restricted Stock Unit Award Agreement (this “Agreement”), Insmed Incorporated (the “Company”) hereby grants an award of [AMOUNT] restricted stock units (the “Restricted Stock Units” or the “RSU Award”) to the individual named above (the “Grantee”).

INSMED INCORPORATED RESTRICTED STOCK UNIT AWARD AGREEMENT UNDER THE AMENDED AND RESTATED 2019 INCENTIVE PLAN FOR NON-U.S. GRANTEES

INSMED INCORPORATED RESTRICTED STOCK UNIT AWARD AGREEMENT UNDER THE AMENDED AND RESTATED 2019 INCENTIVE PLAN FOR NON-U.

INSMED INCORPORATED NON-QUALIFIED STOCK OPTION AGREEMENT UNDER THE AMENDED AND RESTATED 2019 INCENTIVE PLAN FOR NON-U.S. PARTICIPANTS

INSMED INCORPORATED NON-QUALIFIED STOCK OPTION AGREEMENT UNDER THE AMENDED AND RESTATED 2019 INCENTIVE PLAN FOR NON-U.

INSMED INCORPORATED RESTRICTED STOCK UNIT AWARD AGREEMENT UNDER THE AMENDED AND RESTATED 2019 INCENTIVE PLAN FOR U.S. GRANTEES

INSMED INCORPORATED RESTRICTED STOCK UNIT AWARD AGREEMENT UNDER THE AMENDED AND RESTATED 2019 INCENTIVE PLAN FOR U.

Insmed Reports Second-Quarter 2023 Financial Results and Provides Business Update —ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $77.2 Million for the Second Quarter of 2023 Reflects Highest Quarter of Sales Since Launch and 18

Exhibit 99.1 Insmed Reports Second-Quarter 2023 Financial Results and Provides Business Update —ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $77.2 Million for the Second Quarter of 2023 Reflects Highest Quarter of Sales Since Launch and 18% Growth Compared to the Second Quarter of 2022— —Company Raises Full-Year 2023 Guidance Range for Global ARIKAYCE Revenues to $295 Milli

INSMED INCORPORATED PERFORMANCE-BASED RESTRICTED STOCK UNIT AWARD AGREEMENT UNDER THE 2019 INCENTIVE PLAN FOR NON-U.S. GRANTEES

INSMED INCORPORATED PERFORMANCE-BASED RESTRICTED STOCK UNIT AWARD AGREEMENT UNDER THE 2019 INCENTIVE PLAN FOR NON-U.

INSMED INCORPORATED NON-QUALIFIED STOCK OPTION AGREEMENT UNDER THE AMENDED AND RESTATED 2019 INCENTIVE PLAN FOR U.S. PARTICIPANTS

INSMED INCORPORATED NON-QUALIFIED STOCK OPTION AGREEMENT UNDER THE AMENDED AND RESTATED 2019 INCENTIVE PLAN FOR U.

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-30739 INSMED INCO

INSMED INCORPORATED PERFORMANCE-BASED RESTRICTED STOCK UNIT AWARD AGREEMENT UNDER THE 2019 INCENTIVE PLAN FOR U.S. GRANTEES

INSMED INCORPORATED PERFORMANCE-BASED RESTRICTED STOCK UNIT AWARD AGREEMENT UNDER THE 2019 INCENTIVE PLAN FOR U.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 INSMED INCORPORATE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission File

As filed with the Securities and Exchange Commission on May 19, 2023

As filed with the Securities and Exchange Commission on May 19, 2023 Registration No.

CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) Insmed Incorporated (Exact Name of Registrant as Specified in its Charter) Table 1 - Newly Registered Securities

Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) Insmed Incorporated (Exact Name of Registrant as Specified in its Charter) Table 1 - Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTE

Exhibit 25.1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) [] COMPUTERSHARE TRUST COMPANY, NATIONAL ASSOCIATION (Exact name of trustee as specified in its charter)

As filed with the Securities and Exchange Commission on May 19, 2023

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on May 19, 2023 Registration No.

Calculation of Filing Fee Tables Form S-3 (Form Type) INSMED INCORPORATED (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) INSMED INCORPORATED (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Primary Fees to Be Paid Equity Common Stock, $0.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 INSMED INCORPORATED

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission File N

AMENDED AND RESTATED BYLAWS INSMED INCORPORATED ARTICLE I MEETINGS OF SHAREHOLDERS

Exhibit 3.1 AMENDED AND RESTATED BYLAWS of INSMED INCORPORATED ARTICLE I MEETINGS OF SHAREHOLDERS SECTION 1. Place of Meetings. All meetings of the shareholders of Insmed Incorporated (hereinafter called the “Corporation”) shall be held (i) at such place, either within or outside of the Commonwealth of Virginia, as may from time to time be fixed by the Board of Directors of the Corporation (herein

Insmed Unveils New Research Platforms and Capabilities at Investor and Analyst Event, “The Future of Rare at Insmed: Functional Genes, AI-Enhanced Proteins, Glowing Algae, and More” —Early-Stage Research Pillar Anticipated to Generate at Least Six In

Exhibit 99.1 Insmed Unveils New Research Platforms and Capabilities at Investor and Analyst Event, “The Future of Rare at Insmed: Functional Genes, AI-Enhanced Proteins, Glowing Algae, and More” —Early-Stage Research Pillar Anticipated to Generate at Least Six Investigational New Drug (IND) Applications by End of 2025— —Company Reveals Select Initial Disease Targets for Next-Generation Gene Therap

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2023 INSMED INCORPORATED (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2023 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission File Nu

The Future of Rare at Insmed: Functional Genes, AI-Enhanced Proteins, Glowing Algae, and More 6 Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. “Forward-looking statem

Exhibit 99.2 The Future of Rare at Insmed: Functional Genes, AI-Enhanced Proteins, Glowing Algae, and More 6 Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. “Forward-looking statements,” as that term is defined in the Private Securities Litigation Reform Act of 1995, are statements that are not historical facts and

INSMED INCORPORATED NONQUALIFIED STOCK OPTION INDUCEMENT AWARD AGREEMENT

INSMED INCORPORATED NONQUALIFIED STOCK OPTION INDUCEMENT AWARD AGREEMENT No. of shares subject to Option: /$AwardsGranted$/ THIS AGREEMENT dated this /$GrantDate$/ (this “Agreement”), between INSMED INCORPORATED, a Virginia corporation (the “Company”), and /$ParticipantName$/ (the “Participant”), is an inducement material to Participant’s entry into employment with the Company or a subsidiary of t

Insmed Reports First Quarter 2023 Financial Results and Provides Business Update —Enrollment Complete in Phase 3 ASPEN Trial of Brensocatib in Adult Patients with Bronchiectasis; Topline Data Readout on Track for Second Quarter of 2024— —Company to P

Exhibit 99.1 Insmed Reports First Quarter 2023 Financial Results and Provides Business Update —Enrollment Complete in Phase 3 ASPEN Trial of Brensocatib in Adult Patients with Bronchiectasis; Topline Data Readout on Track for Second Quarter of 2024— —Company to Provide Detailed Update on Early-Stage Research Programs on May 8, 2023— —Company on Track to Share Topline Data from Post-Marketing ARISE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 INSMED INCORPORATED (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission File Nu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-30739 INSMED INC

INSMED INCORPORATED NONQUALIFIED STOCK OPTION INDUCEMENT AWARD AGREEMENT

INSMED INCORPORATED NONQUALIFIED STOCK OPTION INDUCEMENT AWARD AGREEMENT No. of shares subject to Option: /$AwardsGranted$/ THIS AGREEMENT dated this /$GrantDate$/ (this “Agreement”), between INSMED INCORPORATED, a Virginia corporation (the “Company”), and /$ParticipantName$/ (the “Participant”), is an inducement material to Participant’s entry into employment with the Company or a subsidiary of t

INSMED INCORPORATED

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Schedule 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

INSMED INCORPORATED

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Schedule 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin

Insmed Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update —Patient Screening Complete in Adult Patients in Phase 3 ASPEN Trial of Brensocatib in Bronchiectasis; Topline Data Readout on Track for Second Quarter of

Exhibit 99.1 Insmed Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update —Patient Screening Complete in Adult Patients in Phase 3 ASPEN Trial of Brensocatib in Bronchiectasis; Topline Data Readout on Track for Second Quarter of 2024— —Company to Share Robust Updates Across Early-Stage Programs at Research Day on May 8, 2023— —Company on Track to Share Topline Da

List of Subsidiaries January 2023 Name Jurisdiction of Incorporation Celtrix Pharmaceuticals, Inc. Delaware Insmed Gene Therapy LLC Delaware Insmed Limited England and Wales Insmed Holdings Limited Ireland Insmed Ireland Limited Ireland Insmed Nether

EXHIBIT 21.1 List of Subsidiaries January 2023 Name Jurisdiction of Incorporation Celtrix Pharmaceuticals, Inc. Delaware Insmed Gene Therapy LLC Delaware Insmed Limited England and Wales Insmed Holdings Limited Ireland Insmed Ireland Limited Ireland Insmed Netherlands Holdings B.V. The Netherlands Insmed Netherlands B.V. The Netherlands Insmed Germany GmbH Germany Insmed France SAS France Insmed G

Fourth Quarter and Full Year 2022 Financial Results February 23, 2023 This presentation contains forward-looking statements that involve substantial risks and uncertainties. “Forward-looking statements,” as that term is defined in the Private Securit

Exhibit 99.2 Fourth Quarter and Full Year 2022 Financial Results February 23, 2023 This presentation contains forward-looking statements that involve substantial risks and uncertainties. “Forward-looking statements,” as that term is defined in the Private Securities Litigation Reform Act of 1995, are statements that are not historical facts and involve a number of risks and uncertainties. Words he

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2023 INSMED INCORPOR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2023 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PUR

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-30739

INSM / Insmed Incorporated / T. Rowe Price Investment Management, Inc. Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) INSMED INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 457669307 (CUSIP NUMBER) December 31, 2022 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is filed:

INSM / Insmed Incorporated / Palo Alto Investors LP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 8)* Insmed Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 457669307 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing o

INSM / Insmed Incorporated / PRICE T ROWE ASSOCIATES INC /MD/ Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 11) INSMED INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 457669307 (CUSIP NUMBER) December 31, 2022 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is filed

INSM / Insmed Incorporated / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 7)* Name of issuer: Insmed Inc. Title of Class of Securities: Common Stock CUSIP Number: 457669307 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13

INSM / Insmed Incorporated / JANUS HENDERSON GROUP PLC - JHG PLC OWNS <5% Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No.: 7* Name of Issuer: INSMED INCORPORATED Title of Class of Securities: Common Stock CUSIP Number: 457669307 Date of Event Which Requires Filing of this Statement: 12/31/2022 Check the appropriate box to designate the rule pursuant to which this Schedule is fil

INSM / Insmed Incorporated / BlackRock Inc. Passive Investment

SC 13G/A 1 us4576693075020323.txt us4576693075020323.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 10) INSMED INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 457669307 - (CUSIP Number) December 31, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to des

INSM / Insmed Incorporated / STATE STREET CORP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 INITIAL FILING INSMED INC (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 457669307 (CUSIP NUMBER) 12/31/2022 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT TO WHICH THIS SCHEDULE IS FILED: (X)

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2023 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission Fil

Insmed Provides Business Updates and Near-Term Strategic Outlook at 41st Annual J.P. Morgan Healthcare Conference —Topline Data from Phase 2 PK/PD Study of Brensocatib in Patients with Cystic Fibrosis Show Clear Dose Response at all Evaluated Doses—

Exhibit 99.1 Insmed Provides Business Updates and Near-Term Strategic Outlook at 41st Annual J.P. Morgan Healthcare Conference ?Topline Data from Phase 2 PK/PD Study of Brensocatib in Patients with Cystic Fibrosis Show Clear Dose Response at all Evaluated Doses? ?Treatment Discontinuation Rate of 15% Reported in Postmarketing ARISE Trial of ARIKAYCE? (amikacin liposome inhalation suspension) in Fr

Investor Presentation January 2023 Forward Looking Statement Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. “Forward-looking statements,” as that term is defined in t

Exhibit 99.2 Investor Presentation January 2023 Forward Looking Statement Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. ?Forward-looking statements,? as that term is defined in the Private Securities Litigation Reform Act of 1995, are statements that are not historical facts and involve a number of risks and uncer

REVENUE INTEREST PURCHASE AGREEMENT DATED AS OF OCTOBER 19, 2022 INSMED INCORPORATED, ORBIMED ROYALTY & CREDIT OPPORTUNITIES IV, LP TABLE OF CONTENTS ARTICLE 1. DEFINITIONS 5 Section 1.01. Definitions 5 Section 1.02.Irish terms 50 ARTICLE II. PURCHAS

Ex. 10.1 Pursuant to Item 601(b)(10)(iv) of Regulation S-K, confidential information (indicated by [***]) has been omitted from Exhibit 10.1 because it (i) is not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. REVENUE INTEREST PURCHASE AGREEMENT DATED AS OF OCTOBER 19, 2022 BETWEEN INSMED INCORPORATED, AND ORBIMED ROYALTY & CREDIT OPPORTUNITIES IV, L

2

EXHIBIT 10.3 August 8, 2022 Roger Adsett Chief Operating Officer 5 Swallow Hill Road Greenville, DE 19807 RE: Employment Agreement Dear Roger, Insmed Incorporated (“Insmed”) and you are parties to the Amended and Restated Employment Agreement, dated April 1, 2022 (the “Agreement”). All capitalized terms not otherwise defined in this letter agreement shall have the meanings ascribed to such terms i

Insmed Reports Third Quarter 2022 Financial Results and Provides Business Update —ARIKAYCE® (amikacin liposome inhalation suspension) Achieves 45% Year Over Year Growth for the Third Quarter of 2022 with Total Revenue of $67.7 Million, Marking the St

Exhibit 99.1 Insmed Reports Third Quarter 2022 Financial Results and Provides Business Update ?ARIKAYCE? (amikacin liposome inhalation suspension) Achieves 45% Year Over Year Growth for the Third Quarter of 2022 with Total Revenue of $67.7 Million, Marking the Strongest Quarter Since Launch? ?Clinical Programs Progressing on Track; Company Expects to Complete Enrollment in Phase 3 ASPEN Trial of B

LOAN AGREEMENT Dated as of October 19, 2022 INSMED INCORPORATED (as Borrower, and a Credit Party), THE GUARANTORS SIGNATORY HERETO OR OTHERWISE PARTY HERETO FROM TIME TO TIME (as additional Credit Parties), BIOPHARMA CREDIT PLC (as Collateral Agent),

Ex. 10.2 Pursuant to Item 601(b)(10)(iv) of Regulation S-K, confidential information (indicated by [***]) has been omitted from Exhibit 10.2 because it (i) is not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed. LOAN AGREEMENT Dated as of October 19, 2022 among INSMED INCORPORATED (as Borrower, and a Credit Party), THE GUARANTORS SIGNATORY HERETO OR OT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-30739 INSMED

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2022 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission Fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 19, 2022 INSMED INCORPORA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 19, 2022 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction (Commission (IRS Employer of inc

Insmed Announces Strategic Financings Totaling $775 Million —$500 million secured in non-dilutive structured financings consisting of a term loan and capped royalty financing— —$275 million underwritten offering of common stock— —Financings increase

EX-99.1 4 ny20005570x4ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Insmed Announces Strategic Financings Totaling $775 Million —$500 million secured in non-dilutive structured financings consisting of a term loan and capped royalty financing— —$275 million underwritten offering of common stock— —Financings increase cash and cash equivalents and marketable securities to approximately $1.3 billion— BRIDGEWA

13,750,000 Shares INSMED INCORPORATED Common Stock, Par Value $0.01 Per Share UNDERWRITING AGREEMENT

Exhibit 1.1 13,750,000 Shares INSMED INCORPORATED Common Stock, Par Value $0.01 Per Share UNDERWRITING AGREEMENT October 19, 2022 J.P. Morgan Securities LLC SVB Securities LLC as Representatives of the several Underwriters c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, NY 10179 c/o SVB Securities LLC 53 State Street, 40th Floor Boston, MA 02109 Ladies and Gentlemen: Insmed Incorporate

13,750,000 Shares

TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration Number 333-238560 PROSPECTUS SUPPLEMENT (To Prospectus dated May 21, 2020) 13,750,000 Shares ? Common Stock We are offering 13,750,000 shares of our common stock.

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 19, 2022 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction (Commission (IRS Employer of inc

Calculation of Filing Fee Tables (Form Type) Insmed Incorporated (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities

Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Insmed Incorporated (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Equity Common stock, par value $0.

INSM / Insmed Incorporated / PRICE T ROWE ASSOCIATES INC /MD/ Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 10) INSMED INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 457669307 (CUSIP NUMBER) July 31, 2022 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is filed: [x

EMPLOYMENT AGREEMENT

EMPLOYMENT AGREEMENT This Employment Agreement (?Agreement?) is effective on May 23, 2022 (the ?Effective Date?), by and between Insmed Incorporated, a Virginia corporation (?Insmed?), and J.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission File

Insmed Reports Second Quarter 2022 Financial Results and Provides Business Update —ARIKAYCE® (amikacin liposome inhalation suspension) Achieves 44% Year Over Year Growth for the Second Quarter of 2022 with Total Revenue of $65.2 Million, Marking the

Exhibit 99.1 Insmed Reports Second Quarter 2022 Financial Results and Provides Business Update ?ARIKAYCE? (amikacin liposome inhalation suspension) Achieves 44% Year Over Year Growth for the Second Quarter of 2022 with Total Revenue of $65.2 Million, Marking the Strongest Quarter Since Launch? ?All Clinical Programs Progressing on Track? ?Company Reiterates Guidance of at Least 30% Revenue Growth

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-30739 INSMED INCO

Insmed Names Drayton Wise Chief Commercial Officer

Exhibit 99.1 Insmed Names Drayton Wise Chief Commercial Officer BRIDGEWATER, N.J., May 23, 2022 /PRNewswire/ ? Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the appointment of Drayton Wise as Chief Commercial Officer, effective May 23, 2022. In addition to his current responsibil

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2022 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction (Commission (IRS Employer of incorpo

As filed with the Securities and Exchange Commission on May 19, 2022

As filed with the Securities and Exchange Commission on May 19, 2022 Registration No.

CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) Insmed Incorporated (Exact Name of Registrant as Specified in its Charter) Table 1 - Newly Registered Securities

Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) Insmed Incorporated (Exact Name of Registrant as Specified in its Charter) Table 1 - Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2022 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction (Commission (IRS Employer of incorpo

AMENDED AND RESTATED EMPLOYMENT AGREEMENT

AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (?Agreement?) is effective on April 1, 2022 (the ?Effective Date?), by and between Insmed Incorporated, a Virginia corporation (?Insmed?), and Sara Bonstein (hereinafter, the ?Executive? and collectively with Insmed, the ?Parties?).

Insmed Reports First Quarter 2022 Financial Results and Provides Business Update —ARIKAYCE® (amikacin liposome inhalation suspension) Achieves 32% Year Over Year Growth for the First Quarter of 2022 with Total Revenue of $53.1 Million— —Seven Clinica

Exhibit 99.1 Insmed Reports First Quarter 2022 Financial Results and Provides Business Update ?ARIKAYCE? (amikacin liposome inhalation suspension) Achieves 32% Year Over Year Growth for the First Quarter of 2022 with Total Revenue of $53.1 Million? ?Seven Clinical Trials Underway; Enrollment on Track in Brensocatib Phase 3 ASPEN Study and ARIKAYCE Post-Marketing Studies (ARISE and ENCORE)? ?Compan

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-30739 INSMED INC

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2022 INSMED INCORPORATED (Exact name of registrant as specified in its charter) Virginia 000-30739 54-1972729 (State or other jurisdiction of incorporation) (Commission File Nu

AMENDED AND RESTATED EMPLOYMENT AGREEMENT

AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (?Agreement?) is effective on April 1, 2022 (the ?Effective Date?), by and between Insmed Incorporated, a Virginia corporation (?Insmed?), and S.

AMENDED AND RESTATED EMPLOYMENT AGREEMENT

AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (?Agreement?) is effective on April 1, 2022 (the ?Effective Date?), by and between Insmed Incorporated, a Virginia corporation (?Insmed?), and Martina Flammer (hereinafter, the ?Executive? and collectively with Insmed, the ?Parties?).

AMENDED AND RESTATED EMPLOYMENT AGREEMENT

AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (?Agreement?) is effective on April 1, 2022 (the ?Effective Date?), by and between Insmed Incorporated, a Virginia corporation (?Insmed?), and Michael Smith (hereinafter, the ?Executive? and collectively with Insmed, the ?Parties?).

AMENDED AND RESTATED EMPLOYMENT AGREEMENT

AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (?Agreement?) is effective on April 1, 2022 (the ?Effective Date?), by and between Insmed Incorporated, a Virginia corporation (?Insmed?), and Roger Adsett (hereinafter, the ?Executive? and collectively with Insmed, the ?Parties?).

INSMED INCORPORATED

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Schedule 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin

INSMED INCORPORATED

DEF 14A 1 ny20001684x1def14a.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Schedule 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant ☑ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (